It takes approx. seven years to diagnose a patient with a rare disease. It doesn’t have to be this way.
We are excited to share that our enhanced Whole Exome Sequencing (WES) solution is now out! All WES samples received by our lab starting 1st June will be on this new enhanced CentoXome®. We are now offering enhanced coverage and performance without additional cost to clinicians and patients!
Our three key updates are seamlessly integrated to help your clients/prospects diagnose complex and unsolved patients cases today:
- Enhanced Coverage
Innovative technology with uniform coverage across the entire exome (~20,000 genes), full mitochondrial genome, and known medically-associated genes and variants
- Increased Diagnostic Yield
By boosting clinically relevant regions and providing panel-grade quality coverage of ~8,000 medically-associated genes, diagnostic yield increases by up to 20% compared to conventional WES
- More Insights
Improved clinical reporting based on bioinformatics, artificial intelligence (AI), and medical expert-based analysis of CENTOGENE’s unique Bio/Databank of ~600,000 patients from >120 countries and >31 million unique variants
More details available via: https://www.centogene.com/de/diagnostics/whole-exome-sequencing.html
We have also released this exciting news at this Media Release link.
To get more technical information about NEW CentoXome, check out the attached Product Sheet below